المصدر: Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754)
Avutu V, Weiss AR, Reed DR, Ahmed SK, Allen-Rhoades WA, Chen YE, Davis LE, Eaton BR, Hawkins DS, Indelicato DJ, Patel SR, Randall RL, Reinke DK, Riedel RF, Scharschmidt TJ, Thornton KA, Wang D, Janeway KA, Kopp LM. Identified Enrollment Challenges of Adolescent and Young Adult Patients on the Nonchemotherapy Arm of Children's Oncology Group Study ARST1321. J Adolesc Young Adult Oncol. 2022 Jun;11(3):328-332. doi: 10.1089/jayao.2021.0103. Epub 2021 Sep 9.
Vatner R, James CD, Sathiaseelan V, Bondra KM, Kalapurakal JA, Houghton PJ. Radiation therapy and molecular-targeted agents in preclinical testing for immunotherapy, brain tumors, and sarcomas: Opportunities and challenges. Pediatr Blood Cancer. 2021 May;68 Suppl 2:e28439. doi: 10.1002/pbc.28439. Epub 2020 Aug 22.
Weiss AR, Chen YL, Scharschmidt TJ, Chi YY, Tian J, Black JO, Davis JL, Fanburg-Smith JC, Zambrano E, Anderson J, Arens R, Binitie O, Choy E, Davis JW, Hayes-Jordan A, Kao SC, Kayton ML, Kessel S, Lim R, Meyer WH, Million L, Okuno SH, Ostrenga A, Parisi MT, Pryma DA, Randall RL, Rosen MA, Schlapkohl M, Shulkin BL, Smith EA, Sorger JI, Terezakis S, Hawkins DS, Spunt SL, Wang D. Pathological response in children and adults with large unresected intermediate-grade or high-grade soft tissue sarcoma receiving preoperative chemoradiotherapy with or without pazopanib (ARST1321): a multicentre, randomised, open-label, phase 2 trial. Lancet Oncol. 2020 Aug;21(8):1110-1122. doi: 10.1016/S1470-2045(20)30325-9. Epub 2020 Jul 20.

المصدر: A Phase 2 Study of GDC-0449 in Patients With Advanced Chondrosarcomas
Italiano A, Le Cesne A, Bellera C, Piperno-Neumann S, Duffaud F, Penel N, Cassier P, Domont J, Takebe N, Kind M, Coindre JM, Blay JY, Bui B. GDC-0449 in patients with advanced chondrosarcomas: a French Sarcoma Group/US and French National Cancer Institute Single-Arm Phase II Collaborative Study. Ann Oncol. 2013 Nov;24(11):2922-6. doi: 10.1093/annonc/mdt391.

المؤلفون: PharmaMar

المصدر: Phase II Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma
Lee AF, Hayes MM, Lebrun D, Espinosa I, Nielsen GP, Rosenberg AE, Lee CH. FLI-1 distinguishes Ewing sarcoma from small cell osteosarcoma and mesenchymal chondrosarcoma. Appl Immunohistochem Mol Morphol. 2011 May;19(3):233-8. doi: 10.1097/PAI.0b013e3181fd6697.
Wang L, Motoi T, Khanin R, Olshen A, Mertens F, Bridge J, Dal Cin P, Antonescu CR, Singer S, Hameed M, Bovee JV, Hogendoorn PC, Socci N, Ladanyi M. Identification of a novel, recurrent HEY1-NCOA2 fusion in mesenchymal chondrosarcoma based on a genome-wide screen of exon-level expression data. Genes Chromosomes Cancer. 2012 Feb;51(2):127-39. doi: 10.1002/gcc.20937. Epub 2011 Oct 27.
Morioka H, Takahashi S, Araki N, Sugiura H, Ueda T, Takahashi M, Yonemoto T, Hiraga H, Hiruma T, Kunisada T, Matsumine A, Susa M, Nakayama R, Nishimoto K, Kikuta K, Horiuchi K, Kawai A. Results of sub-analysis of a phase 2 study on trabectedin treatment for extraskeletal myxoid chondrosarcoma and mesenchymal chondrosarcoma. BMC Cancer. 2016 Jul 14;16:479. doi: 10.1186/s12885-016-2511-y.
Forni C, Minuzzo M, Virdis E, Tamborini E, Simone M, Tavecchio M, Erba E, Grosso F, Gronchi A, Aman P, Casali P, D'Incalci M, Pilotti S, Mantovani R. Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors. Mol Cancer Ther. 2009 Feb;8(2):449-57. doi: 10.1158/1535-7163.MCT-08-0848. Epub 2009 Feb 3.
Huvos AG, Rosen G, Dabska M, Marcove RC. Mesenchymal chondrosarcoma. A clinicopathologic analysis of 35 patients with emphasis on treatment. Cancer. 1983 Apr 1;51(7):1230-7. doi: 10.1002/1097-0142(19830401)51:73.0.co;2-q.

المؤلفون: van Praag, Veroniek M.¹ (AUTHOR) m.a.j.van_de_sande@lumc.nl, Molenaar, Dominique¹ (AUTHOR), Tendijck, Guus A. H.¹ (AUTHOR), Schaap, Gerard R.² (AUTHOR), Jutte, Paul C.³ (AUTHOR), van der Geest, Ingrid C. M.⁴ (AUTHOR) ingrid.vandergeest@radboudumc.nl, Fiocco, Marta^5,6,7 (AUTHOR), van de Sande, Michiel A. J.^1,7 (AUTHOR)

المصدر: Cancers. Oct2024, Vol. 16 Issue 20, p3484. 12p.

مصطلحات موضوعية: *HEALTH status indicators, *CHONDROSARCOMA, *BODY mass index, *RESEARCH funding, *RARE diseases, *SEX distribution, *SMOKING, *MULTIPLE regression analysis, *CANCER patients, *AGE distribution, *TUMOR grading, *DECISION making in clinical medicine, *DECISION making, *RETROSPECTIVE studies, *ONCOLOGY, *TREATMENT effectiveness, *MULTIVARIATE analysis, *LONGITUDINAL method, *KAPLAN-Meier estimator, *LOG-rank test, *RESEARCH, *MEDICAL records, *ACQUISITION of data, *STATISTICS, *SURVIVAL analysis (Biometry), *CONFIDENCE intervals, *HEALTH care teams, *OVERALL survival, *HOSPITAL wards, *COMORBIDITY, *PROPORTIONAL hazards models

مصطلحات جغرافية: NETHERLANDS

Alternate Title: Recuperación de miembro superior con aloinjerto intercalar masivo para condrosarcoma humeral.

المؤلفون: Salcedo, G.¹, Varela, A.¹, Villamues, N.¹ nancy.l.villamues@correounivalle.edu.co

المصدر: Acta Ortopédica Mexicana. sep/oct2024, Vol. 38 Issue 5, p345-350. 6p.

مصطلحات موضوعية: *CHONDROSARCOMA, *MESENCHYMAL stem cells, *HUMERUS, *LIMB salvage, *HOMOGRAFTS

المؤلفون: Lin, Chih‐Yang¹ (AUTHOR), Law, Yat‐Yin^2,3 (AUTHOR), Yu, Cheng‐Chieh⁴ (AUTHOR), Wu, Yu‐Ying^3,5,6 (AUTHOR), Hou, Sheng‐Mou^7,8 (AUTHOR), Chen, Wei‐Li¹ (AUTHOR), Yang, Shang‐Yu⁹ (AUTHOR), Tsai, Chun‐Hao^10,11 (AUTHOR), Lo, Yuan‐Shun^11,12,13 (AUTHOR), Fong, Yi‐Chin^10,11,12 (AUTHOR), Tang, Chih‐Hsin^{4,14,15,16,17} (AUTHOR) chtang@mail.cmu.edu.tw

المصدر: Journal of Cellular Physiology. Sep2024, Vol. 239 Issue 9, p1-15. 15p.

مصطلحات موضوعية: *LYSYL oxidase, *CHONDROSARCOMA, *GENE expression, *CELL migration, *METASTASIS, *LUNGS

المصدر: A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
Tap WD, Cote GM, Burris HA, Gore L, Beeram M, Conley AP, Gianolio DA, Qu Z, Gliser C, Pandya SS, Trent JC. Phase I study of the mutant IDH1 inhibitor ivosidenib: Long-term safety and clinical activity in patients with conventional chondrosarcoma. J Clin Oncol. 2023 May 31;41(16_Supplement):11532. doi: 10.1200/JCO.2023.41.16_suppl.11532
Ellingson BM, Kim GHJ, Brown M, Lee J, Salamon N, Steelman L, Hassan I, Pandya SS, Chun S, Linetsky M, Yoo B, Wen PY, Mellinghoff IK, Goldin J, Cloughesy TF. Volumetric measurements are preferred in the evaluation of mutant IDH inhibition in non-enhancing diffuse gliomas: Evidence from a phase I trial of ivosidenib. Neuro Oncol. 2022 May 4;24(5):770-778. doi: 10.1093/neuonc/noab256.
Aguado-Fraile E, Tassinari A, Ishii Y, Sigel C, Lowery MA, Goyal L, Gliser C, Jiang L, Pandya SS, Wu B, Bardeesy N, Choe S, Deshpande V. Molecular and morphological changes induced by ivosidenib correlate with efficacy in mutant-IDH1 cholangiocarcinoma. Future Oncol. 2021 Jun;17(16):2057-2074. doi: 10.2217/fon-2020-1274. Epub 2021 Mar 12.
Mellinghoff IK, Ellingson BM, Touat M, Maher E, De La Fuente MI, Holdhoff M, Cote GM, Burris H, Janku F, Young RJ, Huang R, Jiang L, Choe S, Fan B, Yen K, Lu M, Bowden C, Steelman L, Pandya SS, Cloughesy TF, Wen PY. Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Advanced Glioma. J Clin Oncol. 2020 Oct 10;38(29):3398-3406. doi: 10.1200/JCO.19.03327. Epub 2020 Jun 12.
Tap WD, Villalobos VM, Cote GM, Burris H, Janku F, Mir O, Beeram M, Wagner AJ, Jiang L, Wu B, Choe S, Yen K, Gliser C, Fan B, Agresta S, Pandya SS, Trent JC. Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma. J Clin Oncol. 2020 May 20;38(15):1693-1701. doi: 10.1200/JCO.19.02492. Epub 2020 Mar 24.
Lowery MA, Burris HA 3rd, Janku F, Shroff RT, Cleary JM, Azad NS, Goyal L, Maher EA, Gore L, Hollebecque A, Beeram M, Trent JC, Jiang L, Fan B, Aguado-Fraile E, Choe S, Wu B, Gliser C, Agresta SV, Pandya SS, Zhu AX, Abou-Alfa GK. Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study. Lancet Gastroenterol Hepatol. 2019 Sep;4(9):711-720. doi: 10.1016/S2468-1253(19)30189-X. Epub 2019 Jul 9.
Fan B, Mellinghoff IK, Wen PY, Lowery MA, Goyal L, Tap WD, Pandya SS, Manyak E, Jiang L, Liu G, Nimkar T, Gliser C, Prahl Judge M, Agresta S, Yang H, Dai D. Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors. Invest New Drugs. 2020 Apr;38(2):433-444. doi: 10.1007/s10637-019-00771-x. Epub 2019 Apr 26.

Other URLs: https://clinicaltrials.servier.com/
https://clinicaltrials.servier.com/wp-content/uploads/AG120-C-002-anonymised-synopsis-2024.09.12.pdf
https://clinicaltrials.servier.com/wp-content/uploads/AG120-C-002-laysummary-2024.11.18.en_.pdf

المصدر: Phase II Study of Enasidenib in IDH2-mutated Malignant Sinonasal and Skull Base Tumors

المؤلفون: Centre François Baclesse, Centre de lutte contre le cancer (CLCC)

المصدر: Descriptive Cohort of French Patients Treated with Carbonetherapy Since October 2010 Outside PHRC-ETOILE - PRIMHADRON

المصدر: A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma

المؤلفون: TRACER Europe BV

المصدر: The Safety, Tolerability and Biodistribution of a Single Intravenous Administration of Two Zirconium-89 Labelled Vartumabs (F8scFV or C9scFv) in Patients with Solid Tumors - a Phase 0, Open Label, PET/CT Molecular Imaging Basket Trial

المصدر: A Phase 2 Study of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma
Sheikh TN, Chen X, Xu X, McGuire JT, Ingham M, Lu C, Schwartz GK. Growth Inhibition and Induction of Innate Immune Signaling of Chondrosarcomas with Epigenetic Inhibitors. Mol Cancer Ther. 2021 Dec;20(12):2362-2371. doi: 10.1158/1535-7163.MCT-21-0066. Epub 2021 Sep 22.

Other URLs: https://grants.nih.gov/policy/sharing.htm

المصدر: A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Chondrosarcoma and Clear Cell Sarcoma

Other URLs: https://grants.nih.gov/policy/sharing.htm

المصدر: The Registry of Oncology Outcomes Associated with Testing and Treatment (ROOT)
Woodcock J, LaVange LM. Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both. N Engl J Med. 2017 Jul 6;377(1):62-70. doi: 10.1056/NEJMra1510062. No abstract available.
Boland JF, Chung CC, Roberson D, Mitchell J, Zhang X, Im KM, He J, Chanock SJ, Yeager M, Dean M. The new sequencer on the block: comparison of Life Technology's Proton sequencer to an Illumina HiSeq for whole-exome sequencing. Hum Genet. 2013 Oct;132(10):1153-63. doi: 10.1007/s00439-013-1321-4. Epub 2013 Jun 12.
Morash M, Mitchell H, Beltran H, Elemento O, Pathak J. The Role of Next-Generation Sequencing in Precision Medicine: A Review of Outcomes in Oncology. J Pers Med. 2018 Sep 17;8(3):30. doi: 10.3390/jpm8030030.
Korphaisarn K, Kopetz S. BRAF-Directed Therapy in Metastatic Colorectal Cancer. Cancer J. 2016 May-Jun;22(3):175-8. doi: 10.1097/PPO.0000000000000189.
Sherman RE, Anderson SA, Dal Pan GJ, Gray GW, Gross T, Hunter NL, LaVange L, Marinac-Dabic D, Marks PW, Robb MA, Shuren J, Temple R, Woodcock J, Yue LQ, Califf RM. Real-World Evidence - What Is It and What Can It Tell Us? N Engl J Med. 2016 Dec 8;375(23):2293-2297. doi: 10.1056/NEJMsb1609216. No abstract available.
Kaplan RM, Chambers DA, Glasgow RE. Big data and large sample size: a cautionary note on the potential for bias. Clin Transl Sci. 2014 Aug;7(4):342-6. doi: 10.1111/cts.12178. Epub 2014 Jul 15.
AACR Project GENIE Consortium. AACR Project GENIE: Powering Precision Medicine through an International Consortium. Cancer Discov. 2017 Aug;7(8):818-831. doi: 10.1158/2159-8290.CD-17-0151. Epub 2017 Jun 1.
Dickson DJ, Pfeifer JD. Real-world data in the molecular era-finding the reality in the real world. Clin Pharmacol Ther. 2016 Feb;99(2):186-97. doi: 10.1002/cpt.300. Epub 2016 Jan 12.
Conley RB, Dickson D, Zenklusen JC, Al Naber J, Messner DA, Atasoy A, Chaihorsky L, Collyar D, Compton C, Ferguson M, Khozin S, Klein RD, Kotte S, Kurzrock R, Lin CJ, Liu F, Marino I, McDonough R, McNeal A, Miller V, Schilsky RL, Wang LI. Core Clinical Data Elements for Cancer Genomic Repositories: A Multi-stakeholder Consensus. Cell. 2017 Nov 16;171(5):982-986. doi: 10.1016/j.cell.2017.10.032.

المصدر: A Phase 1 Open-Label, Dose-Escalation and Dose-Expansion Study to Investigate the Safety, Pharmacokinetics, and Anti-Tumor Activity of IACS-6274 as Monotherapy and in Combination in Patients With Advanced Solid Tumors

المؤلفون: Institut de Recherches Internationales Servier

المصدر: A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Study of Ivosidenib in Participants ≥18 Years of Age With Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen

Other URLs: http://clinicaltrials.servier.com/

المصدر: A Randomized Phase II, Placebo-controlled, Multicenter Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas
Duffaud F, Italiano A, Bompas E, Rios M, Penel N, Mir O, Piperno-Neumann S, Chevreau C, Delcambre C, Bertucci F, Boudou-Rouquette P, Cancel M, Perrin C, Saada-Bouzid E, Monard L, Schiffler C, Chaigneau L, Hervieu A, Collard O, Bouvier C, Vidal V, Chabaud S, Blay JY; French Sarcoma Group. Efficacy and safety of regorafenib in patients with metastatic or locally advanced chondrosarcoma: Results of a non-comparative, randomised, double-blind, placebo controlled, multicentre phase II study. Eur J Cancer. 2021 Jun;150:108-118. doi: 10.1016/j.ejca.2021.03.039. Epub 2021 Apr 22.
Hattinger CM, Patrizio MP, Magagnoli F, Luppi S, Serra M. An update on emerging drugs in osteosarcoma: towards tailored therapies? Expert Opin Emerg Drugs. 2019 Sep;24(3):153-171. doi: 10.1080/14728214.2019.1654455. Epub 2019 Aug 14.
Duffaud F, Mir O, Boudou-Rouquette P, Piperno-Neumann S, Penel N, Bompas E, Delcambre C, Kalbacher E, Italiano A, Collard O, Chevreau C, Saada E, Isambert N, Delaye J, Schiffler C, Bouvier C, Vidal V, Chabaud S, Blay JY; French Sarcoma Group. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol. 2019 Jan;20(1):120-133. doi: 10.1016/S1470-2045(18)30742-3. Epub 2018 Nov 23.

المؤلفون: Almanzo, Santiago¹ (AUTHOR), Saro-Buendía, Miguel^1,2 (AUTHOR) misabuen@alumni.uv.es, Iommi Diez, Sara³ (AUTHOR), Bancalari Díaz, Catalina¹ (AUTHOR), García Piñero, Alfonso^1,2 (AUTHOR), Armengot Carceller, Miguel^1,2 (AUTHOR)

المصدر: Indian Journal of Otolaryngology & Head & Neck Surgery. Aug2024, Vol. 76 Issue 4, p3576-3579. 4p.

مصطلحات موضوعية: *PARANASAL sinuses, *CHONDROSARCOMA, *TUMORS, *DIAGNOSIS

المؤلفون: Van Den Berghe, Thomas^1,2 (AUTHOR) thovdnbe.VanDenBerghe@UGent.be, Delbare, Felix^1,2 (AUTHOR), Candries, Esther^1,2 (AUTHOR), Lejoly, Maryse^1,2 (AUTHOR), Algoet, Chloé^1,2 (AUTHOR), Chen, Min³ (AUTHOR), Laloo, Frederiek^1,2 (AUTHOR), Huysse, Wouter C. J.^1,2 (AUTHOR), Creytens, David⁴ (AUTHOR), Verstraete, Koenraad L.^1,2 (AUTHOR)

المصدر: European Radiology. Aug2024, Vol. 34 Issue 8, p4988-5006. 19p.

مصطلحات موضوعية: *CHONDROSARCOMA, *CARTILAGE, *HUMERUS, *BENIGN tumors, *DELAYED diagnosis, *TUMORS

المؤلفون: Sikdar, Debanjan¹ (AUTHOR) debanjansikdar@gmail.com, Gupta, Sweety¹ (AUTHOR), Roshan, Ravi¹ (AUTHOR), Agarwal, Shruti² (AUTHOR), Joseph, Deepa M.¹ (AUTHOR), Gupta, Manoj¹ (AUTHOR)

المصدر: Indian Journal of Medical & Paediatric Oncology. Aug2024, Vol. 45 Issue 4, p351-356. 6p.

مصطلحات موضوعية: *CHONDROSARCOMA, *CHILD patients, *YOUNG adults